Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 1881, March 15, 2008. doi: 10.1158/0008-5472.CAN-07-1597
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamaguchi, N.
Right arrow Articles by Watanabe, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamaguchi, N.
Right arrow Articles by Watanabe, S.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

NOTCH3 Signaling Pathway Plays Crucial Roles in the Proliferation of ErbB2-Negative Human Breast Cancer Cells

Noritaka Yamaguchi1,4, Tetsunari Oyama10, Emi Ito6, Hitoshi Satoh5, Sakura Azuma4, Mitsuhiro Hayashi11, Ken Shimizu13, Reiko Honma6, Yuka Yanagisawa6, Akira Nishikawa6,8,9, Mika Kawamura6,9, Jun-ichi Imai6,7, Susumu Ohwada12, Kuniaki Tatsuta2, Jun-ichiro Inoue4, Kentaro Semba1,4,3 and Shinya Watanabe6,7

1 Consolidated Research Institute for Advanced Science and Medical Care, Departments of 2 Applied Chemistry and 3 Life Science and Medical Bioscience, School of Science and Engineering, Waseda University; 4 Department of Cellular and Molecular Biology, Institute of Medical Science and 5 Department of Medical Genome Sciences, Graduate School of Frontier Sciences, University of Tokyo; 6 Department of Clinical Informatics, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University; 7 Expression Profiles Team, Biological Information Research Center, National Institute of Advanced Industrial Science and Technology; 8 Nippon Gene, Co., Ltd.; and 9 Medicrome, Inc., Tokyo, Japan; Departments of 10 Pathology and 11 Surgical Oncology, Dokkyo Medical University School of Medicine, Tochigi, Japan; 12 Department of Surgery, Gunma University, Graduate School of Medicine, Gunma, Japan; and 13 Department of Pathology, Saitama Social Insurance Hospital, Saitama, Japan

Requests for reprints: Kentaro Semba, Division of Cellular and Molecular Biology, Department of Cancer Biology, The Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-35449-5278; Fax: 81-35449-5278; E-mail: ksemba{at}waseda.jp.

Key Words: Breast cancer • Cell growth/signaling pathways • Gene amplification • Molecular oncology

ErbB2-negative breast tumors represent a significant therapeutic hurdle because of a lack of effective molecular targets. Although NOTCH proteins are known to be involved in mammary tumorigenesis, the functional significance of these proteins in ErbB2-negative breast tumors is not clear. In the present study, we examined the expression of activated NOTCH receptors in human breast cancer cell lines, including ErbB2-negative and ErbB2-positive cell lines. Activated NOTCH1 and NOTCH3 proteins generated by {gamma}-secretase were detected in most of the cell lines tested, and both proteins activated CSL-mediated transcription. Down-regulation of NOTCH1 by RNA interference had little or no suppressive effect on the proliferation of either ErbB2-positive or ErbB2-negative cell lines. In contrast, down-regulation of NOTCH3 significantly suppressed proliferation and promoted apoptosis of the ErbB2-negative tumor cell lines. Down-regulation of NOTCH3 did not have a significant effect on the ErbB2-positive tumor cell lines. Down-regulation of CSL also suppressed the proliferation of ErbB2-negative breast tumor cell lines, indicating that the NOTCH-CSL signaling axis is involved in cell proliferation. Finally, NOTCH3 gene amplification was detected in a breast tumor cell line and one breast cancer tissue specimen even though the frequency of NOTCH3 gene amplification was low (<1%). Taken together, these findings indicate that NOTCH3-mediated signaling rather than NOTCH1-mediated signaling plays an important role in the proliferation of ErbB2-negative breast tumor cells and that targeted suppression of this signaling pathway may be a promising strategy for the treatment of ErbB2-negative breast cancers. [Cancer Res 2008;68(6):1881–8]




This article has been cited by other articles:


Home page
Cancer Res.Home page
O. Meurette, S. Stylianou, R. Rock, G. M. Collu, A. P. Gilmore, and K. Brennan
Notch Activation Induces Akt Signaling via an Autocrine Loop to Prevent Apoptosis in Breast Epithelial Cells
Cancer Res., June 15, 2009; 69(12): 5015 - 5022.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Meng, X. Zhang, K. D. Hankenson, and M. M. Wang
Thrombospondin 2 Potentiates Notch3/Jagged1 Signaling
J. Biol. Chem., March 20, 2009; 284(12): 7866 - 7874.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Xiao, Y. Ye, K. Yearsley, S. Jones, and S. H. Barsky
The Lymphovascular Embolus of Inflammatory Breast Cancer Expresses a Stem Cell-Like Phenotype
Am. J. Pathol., August 1, 2008; 173(2): 561 - 574.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.